As of Jun 29, 2018 Zosano Pharma Corporation (NASDAQ:ZSAN) Sellers Reduced Their Shorts By 43.02%

June 29, 2018 - By Darrin Badillo

It was reported a decrease on Zosano Pharma Corporation (NASDAQ:ZSAN)’s short interest with 43.02%. FINRA announced short interest of ZSAN’s total 924,200 shares. That’s 43.02% down from 1.62M shares. 2 days will cost ZSAN with 523,600 average volume to recover its previous position. 2.89% is Zosano Pharma Corporation float short.

ZSAN is reaching $4.06 during the last trading session, after increased 2.01%.Currently Zosano Pharma Corporation is downtrending after 85.30% change in last June 29, 2017. ZSAN has 185,578 shares volume. The stock underperformed the S&P500 by 97.87%.

Zosano Pharma Corporation, a clinical stage pharmaceutical company, develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients.The firm is worth $48.61 million. The Company’s lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.Currently it has negative earnings.

For more Zosano Pharma Corporation (NASDAQ:ZSAN) news posted briefly go to: Streetinsider.com, Globenewswire.com, Benzinga.com, Streetinsider.com or Benzinga.com. The titles are as follows: “UPDATE: BTIG Starts Zosano Pharma (ZSAN) at Buy” posted on June 27, 2018, “Market Trends Toward New Normal in ANSYS, Pearson, Qualys, HB Fuller, Cabot Microelectronics, and Zosano …” on May 31, 2018, “48 Biggest Movers From Yesterday” with a publish date: June 29, 2018, “Zosano Pharma (ZSAN) Announces Publication of Study on ADAM Technology for Delivery of Zolmitriptan” and the last “60 Biggest Movers From Yesterday” with publication date: June 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: